程序化细胞死亡蛋白(programmed death 1, PD-1) /程序化细胞死亡配体-1 (programmed death ligand 1, PD-L1)抑制剂近年来开始用于非小细胞肺癌(non-small cell lung cancer, NSCLC)的免疫治疗。单独应用免疫治疗,或联合化疗进行治疗,目前已被列入进展期/晚期无表皮生长因子受体(epidermal growth factor receptor, EGFR)、间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)或ROS1突变NSCLC的初始治疗中[1]。. Here, EGFR is linked to non-small cell lung carcinoma.